A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612

Affiliations

¹ McGill University - Jewish General Hospital, Montreal, Canada.
² Medical College of Wisconsin, Milwaukee, WI, USA.
³ SWOG Statistics and Data Management Center, Seattle, WA, USA.
⁴ Queen's University, Kingston, Canada.
⁵ Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁶ Washington University School of Medicine, St. Louis, MO, USA.
⁷ Kaiser Permanente NCAL, Roseville, CA, USA.
⁸ Kaiser Permanente, Santa Clara, CA, USA.
⁹ Moffitt Cancer Center, Tampa, FL, USA.
¹⁰ University of Oklahoma HSC, Oklahoma City, OK, USA.
¹¹ Illinois CancerCare/Heartland NCORP, Peoria, IL, USA.
¹² SWOG Data Operations Center/Cancer Research and Biostatistics, Seattle, WA, USA.
¹³ Cancer Therapy and Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, USA.
¹⁴ Duke University Medical Center, Duke Cancer Institute, Durham, NC, USA.

Clinical Trial

Sarit Assouline et al. Leuk Lymphoma. 2023 Feb.

. 2023 Feb;64(2):473-477.

doi: 10.1080/10428194.2022.2148212. Epub 2022 Dec 14.

¹ McGill University - Jewish General Hospital, Montreal, Canada.
² Medical College of Wisconsin, Milwaukee, WI, USA.
³ SWOG Statistics and Data Management Center, Seattle, WA, USA.
⁴ Queen's University, Kingston, Canada.
⁵ Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
⁶ Washington University School of Medicine, St. Louis, MO, USA.
⁷ Kaiser Permanente NCAL, Roseville, CA, USA.
⁸ Kaiser Permanente, Santa Clara, CA, USA.
⁹ Moffitt Cancer Center, Tampa, FL, USA.
¹⁰ University of Oklahoma HSC, Oklahoma City, OK, USA.
¹¹ Illinois CancerCare/Heartland NCORP, Peoria, IL, USA.
¹² SWOG Data Operations Center/Cancer Research and Biostatistics, Seattle, WA, USA.
¹³ Cancer Therapy and Evaluation Program (CTEP), National Cancer Institute, Bethesda, MD, USA.
¹⁴ Duke University Medical Center, Duke Cancer Institute, Durham, NC, USA.

No abstract available

Figures

1. Fenaux P, Mufti GJ, Santini V, et al. Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. Blood 2007; 110(11): 817-.
1. Serroukh Y, Hebert J, Busque L, et al. Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Rev 2022: 100991. - PubMed
1. Beyar-Katz O, Gill S. Novel Approaches to Acute Myeloid Leukemia Immunotherapy. Clin Cancer Res 2018; 24(22): 5502–15. - PubMed
1. Williams P, Basu S, Garcia-Manero G, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer 2019; 125(9): 1470–81. - PMC - PubMed
1. Vadakekolathu J, Minden MD, Hood T, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci Transl Med 2020; 12(546). - PMC - PubMed